提名人广誉远中药股份有限公司董事会，现提名王继军为广 誉远中药股份有限公司第八届董事会独立董事候选人，并已充分 了解被提名人职业、学历、职称、详细的工作经历、全部兼职、 有无重大失信等不良记录等情况。被提名人已同意出任广誉远中 药股份有限公司第八届董事会独立董事候选人（参见该独立董事 候选人声明）。提名人认为，被提名人具备独立董事任职资格， 与广誉远中药股份有限公司之间不存在任何影响其独立性的关 系，具体声明并承诺如下： 一、被提名人具备上市公司运作的基本知识，熟悉相关法律、 行政法规、规章及其他规范性文件，具有 5 年以上法律、经济、 会计、财务、管理或者其他履行独立董事职责所必需的工作经验。 独立董事提名人声明与承诺 被提名人已经参加培训并取得证券交易所认可的相关培训 证明材料。 二、被提名人任职资格符合下列法律、行政法规和部门规章 的要求： （一）《中华人民共和国公司法》关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的 规定（如适用）； （三）中国证监会《上市公司独立董事管理办法》、上海证 券交易所自律监管规则以及公司章程有关独立董事任职资格和 条件的相关规定； （四）中共 ...

是公司广预演的一个交流我们也很荣幸的邀请到了公司领导唐总来和我们进行今天的一个交流今天我们交流主要分为两个部分第一部分是公司的介绍第二部分是一个科学问答的环节首先有请公司领导唐总用20到30分钟的时间对公司的经营情况和最新进展做一个讲解有请唐总好的感谢主持人也感谢黄安给这样一次机会 我们来交流的大家对广远的这个熟悉程度是首次听呢还是之前有过接触那我还是把广远的提前介绍我们相关的一些公司的背景的情况和大家简要做一个介绍那么说到广远呢我们通常讲我们的名片简单的123451是我们是一个中华老字号企业这个是在06年 首批获得国家商务部颁发的老字号企业两个国家级的秘密技术是指我们的灰灵级产品和订婚单产品的炮制工艺三项国家级的非物质文化遗产是指两个保密的品种再加上我们的安宫牛皇丸的这个炮制工艺四款核心产品前面也讲到了三个了再加上我们的牛皇清新丸 五就是我们五百年的传承发展的历史我们广育园是始于1541年距今有473年的历史了那么这张片子大家可以看到从1541年广圣号开始我们广育园 成为企业型的制造的这个药店的前身就是跟广育园的直接相关联的而不是说前面是个什么这个号那个号之类的一直延续下来的不断在传承的一家制药的生产企业直 ...

Group 1: Investor Relations and Brand Image - The company acknowledges the importance of utilizing shareholder resources and market attention to enhance brand and market image, encouraging interactions between mid-level management and shareholders to address issues [2][3] - The company is committed to maintaining open communication channels with shareholders to improve brand reputation and operational quality, ultimately benefiting all shareholders [3] Group 2: Market Performance and Shareholder Concerns - The company has over 60,000 small shareholders, many of whom have held shares since the state-owned enterprise took over in 2021, expressing concerns over stagnant stock prices and management's perceived indifference to market trends [3][4] - The management emphasizes its awareness of secondary market trends and values shareholder feedback, pledging to improve operational quality and maintain shareholder support [4] Group 3: Business Development and Product Strategy - The company does not have a fixed number of new store openings planned but prioritizes the quality of new stores over quantity [4] - There are no current plans to launch an OTC version of the product "Gui Ling Ji" due to various policy restrictions, but the company will continue to monitor policy changes [4] Group 4: Financial Obligations and Compensation - The company has requested cash compensation of CNY 853.6397 million from Dongsheng Group and is actively communicating to ensure compliance with performance commitments [4][7] - If an agreement cannot be reached with Dongsheng Group, the company will pursue legal avenues to protect the interests of the company and its investors [7][8] Group 5: Marketing and Brand Promotion - The company recognizes its brand awareness is relatively low and plans to enhance promotion through various channels, including cultural dissemination and participation in industry events [5] - The company is focusing on a "Big Product +" strategy, emphasizing core products like "Gui Ling Ji" and expanding into health food categories [5][6] Group 6: Financial Management and Compliance - The company has undergone a thorough review of historical financial issues since relocating its headquarters back to Shanxi in 2022, addressing past discrepancies in revenue and expenses [6] - The company is committed to improving internal controls and financial disclosure quality to mitigate risks of delisting, with no current risk of delisting according to recent regulations [18][19] Group 7: Future Planning and Strategic Goals - The company aims to set revenue and profit targets based on actual business conditions, focusing on high-quality traditional Chinese medicine production [19] - The company plans to hold its 2023 annual shareholder meeting by June 30, 2024, and is actively working on performance compensation issues with Dongsheng Group [21]

证券代码： 600771 证券简称：广誉远 广誉远中药股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|---------------------------|-----------------------------------------------------------| | | | | | | | □特定对象调研 □ 分析师会议 | | 投资者关系活动 | □ | 媒体采访 √ 业绩说明会 | | 类别 | □ | 新闻发布会 □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 投资者网上提问 | | | 人员姓名 | | | | 时间 | 2024 年 5 月 20 | 日 (周一) 下午 15:00~17:00 | | | 公 司 通 过 | 全 景 网 " 投 资 者 关 系 互 动 平 台 " （ https:// | | 地点 | ir.p5w.net | ）采用网络远程的方式召开业绩说明会 | | | 1、副总裁、财务总监王俊波 | | | 上市公司接待人 ...

证券代码：600771 证券简称：广誉远 编号：临 2024-024 广誉远中药股份有限公司 关于子公司收到政府补助的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 对当期损益的影响：2024 年 1 月 1 日至今，广誉远中药股份有限公司 （以下简称"公司"）子公司收到的政府补助均与收益相关，将直接计入损益, 具 体的会计处理以及对公司损益的影响最终以审计机构年度审计确认后的结果为 准。 一、获得补助的基本情况 2024 年 1 月 1 日至今，公司相关子公司累计收到与收益相关的政府补助共计 12,782,296.00 元，占公司 2023 年度经审计归属于上市公司股东的净利润的 14.19%，具体情况如下： 单位：元 | 序号 | 获得时间 | 补助类型 | 补助金额 | 占公司最近一期经审计 净利润的比例（%） | | | --- | --- | --- | --- | --- | --- | | 1 | 2024/1/26 | 与收益相关 | 100,000.00 | | 0.11 | | 2 | ...

Group 1: Event Announcement - Guangyuyuan Traditional Chinese Medicine Co., Ltd. will participate in the "2024 Investor Online Collective Reception Day and Annual Report Performance Briefing" organized by the Shanxi Regulatory Bureau of the China Securities Regulatory Commission, Shanxi Listed Companies Association, and Shenzhen Panorama Network Co., Ltd. [2][3] - The event will be held online on May 20, 2024, from 15:00 to 17:00, allowing investors to engage through the "Panorama Roadshow" website, WeChat, or the Panorama Roadshow APP [3]. Group 2: Communication and Interaction - Company executives will communicate with investors regarding the 2023 annual performance, corporate governance, development strategy, operational status, and sustainable development during the event [3]. - Investors are encouraged to participate actively and provide questions or topics of interest in advance via phone or email [3]. Group 3: Contact Information - Contact person: Qiao Li - Phone: 0351-7099061 - Fax: 0351-7099130 - Email: irm@guangyuyuan.com [4].

证券代码：600771 证券简称：广誉远 编号：临 2024-022 广誉远中药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广誉远中药股份有限公司（以下简称"公司"）董事会于近日收到独立董事甄雪燕女 士的书面辞职申请，甄雪燕女士因个人原因，申请辞去公司独立董事及董事会各专门委 员会职务，辞职后，甄雪燕女士不再担任公司任何职务。 鉴于甄雪燕女士的辞职将导致公司独立董事的人数少于董事会成员的三分之一以及 公司董事会提名委员会、董事会薪酬与考核委员会、董事会战略委员会中独立董事的 人数低于法定人数，根据《公司法》、《上海证券交易所股票上市规则》、《上市公司独 立董事管理办法》、《上市公司自律监管指引第 1 号——规范运作》及《公司章程》等 相关规定，甄雪燕女士的辞职申请将在公司补选产生新任独立董事且公司董事会、董事 会提名委员会、董事会薪酬与考核委员会、董事会战略委员会中独立董事的人数符合 法定人数后方能生效。在此之前，为保证公司董事会的正常运作，甄雪燕女士仍将按照 相关法律法规的规定，继续履行独立董事职责。公司将 ...

广誉远中药股份有限公司 2023 年年度报告 报告期末公司前三年主要会计数据和财务指标的说明 √适用 □不适用 报告期内，公司狠抓"三强两降一控"工作，推动效率、效益双提升。一是稳步 推进"强中台、强学术、强动销"工作，通过"强化中台管理和服务职能、增强学术 转化、增加终端地推活动"三大举措，推动销售额增长，营业收入较上年同期增长 13.56%。二是持续深化"降应收、降成本"工作，通过"老账清收""现款发货"等 举措，推动经营现金流大幅增长、带息负债规模持续降低，财务费用同比下降 38.18%； 通过"降本增效"行动，使产品毛利率提高至 72.94%，同比增长 5.42 个百分点。三 是坚持落实"控渠道"工作，通过"加强渠道管控"和"鼓励优秀的合作伙伴"等举 措，保证商业库存良性和销售渠道可控，在一定程度上保证了经营质量和品牌形象， 助力公司效益的持续提升。截至报告期末，应收账款余额较期初降低 3.62 亿元，下 降 34.23%。 (一)同时按照国际会计准则与按中国会计准则披露的财务报告中净利润和归属于上 市公司股东的净资产差异情况 (三)境内外会计准则差异的说明： □适用 √不适用 2024 年 1 月 ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥343,378,924.32, a decrease of 11.13% compared to ¥369,045,043.47 in the same period last year[6] - Net profit attributable to shareholders was ¥41,303,613.94, representing a significant increase of 49.61% from ¥9,790,453.11 in the previous year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥48,493,985.69, up 76.13% from ¥9,714,819.20 year-on-year[6] - Basic earnings per share increased to ¥0.0844, a rise of 49.65% compared to ¥0.0200 in the same period last year[9] - The weighted average return on equity rose to 2.72%, an increase of 0.79 percentage points from 0.57% in the previous year[9] - The net profit for Q1 2024 reached CNY 49,621,931.14, an increase of 76.3% compared to CNY 28,160,560.34 in Q1 2023[35] - The total comprehensive income for Q1 2024 was CNY 49,621,931.14, up from CNY 28,160,560.34 in Q1 2023, indicating an increase of about 76.3%[37] - Basic and diluted earnings per share for Q1 2024 were both CNY 0.0844, compared to CNY 0.0564 in Q1 2023, reflecting a rise of approximately 49.5%[37] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,605,673,989.81, a decrease of 0.87% from ¥2,628,413,544.42 at the end of the previous year[9] - The equity attributable to shareholders increased to ¥1,537,431,255.25, reflecting a growth of 2.76% from ¥1,496,127,641.31 at the end of the previous year[9] - The total assets of the company amounted to approximately RMB 2.61 billion, a slight decrease from RMB 2.63 billion in the previous period, reflecting a change of about 1.4%[25] - The company's non-current liabilities include short-term borrowings of RMB 56 million, which remained relatively stable compared to RMB 56.06 million previously[25] - Total liabilities decreased to CNY 1,048,188,351.22 from CNY 1,120,549,836.97 at the end of 2023[26] - Shareholders' equity increased to CNY 1,557,485,638.59 from CNY 1,507,863,707.45 at the end of 2023[26] Cash Flow - The net cash flow from operating activities was ¥129,411,721.98, down 5.01% from ¥136,238,575.27 in the same period last year[6] - Cash inflows from operating activities in Q1 2024 totaled CNY 435,091,939.39, compared to CNY 353,669,065.15 in Q1 2023, marking an increase of about 23.0%[40] - Cash outflows from operating activities in Q1 2024 were CNY 305,680,217.41, up from CNY 217,430,489.88 in Q1 2023, which is an increase of approximately 40.5%[40] - The net cash flow from operating activities for Q1 2024 was CNY 129,411,721.98, slightly down from CNY 136,238,575.27 in Q1 2023, a decrease of about 5.9%[40] - Cash inflows from investment activities in Q1 2024 were CNY 1,564,919.86, compared to CNY 581,676.05 in Q1 2023, representing an increase of approximately 169.5%[40] - Cash outflows from investment activities in Q1 2024 were CNY 378,462.81, down from CNY 824,432.45 in Q1 2023, indicating a decrease of about 54.1%[40] - The net cash flow from investment activities for Q1 2024 was CNY 1,186,457.05, a significant improvement from a net outflow of CNY 242,756.40 in Q1 2023[40] - The company reported a significant increase in cash and cash equivalents, with a total of CNY 383,448,177.87 at the end of Q1 2024, compared to CNY 273,891,195.81 at the end of Q1 2023, reflecting a growth of approximately 40.0%[42] Operational Efficiency - The company implemented cost control measures, leading to improved profitability and a higher gross profit margin compared to the previous year[13] - Total operating costs for Q1 2024 were CNY 281,233,386.82, down 20.2% from CNY 352,387,369.66 in Q1 2023[35] - The company reported a total of CNY 62,231,217.98 in operating profit for Q1 2024, compared to CNY 34,572,023.30 in Q1 2023, reflecting a significant improvement[35] - Research and development expenses for Q1 2024 were CNY 8,983,874.58, a slight increase from CNY 8,772,467.17 in Q1 2023[35] - Sales expenses for Q1 2024 were CNY 158,634,670.62, down 24.7% from CNY 210,718,672.14 in Q1 2023[35] Regulatory and Compliance Issues - The company received a notice from the China Securities Regulatory Commission regarding an investigation for suspected violations of information disclosure laws[21] - The company announced corrections and retrospective adjustments to financial statements from 2016 to 2022, impacting the first three quarters of 2023[21] - The company is under disciplinary action from the Shanghai Stock Exchange due to violations related to financial reporting[22]

当事人： 广誉远中药股份有限公司，A 股证券简称：广誉远，A 股证 券代码：600771； 张 斌，广誉远中药股份有限公司时任董事长、总经理、董 事； 上海证券交易所 纪律处分决定书 〔2024〕68 号 关于对广誉远中药股份有限公司及有关 责任人予以纪律处分的决定 傅淑红，广誉远中药股份有限公司时任董事、财务总监、副 -1- ──────────────────────── 总经理； 王俊波，广誉远中药股份有限公司时任财务总监； 张正治，广誉远中药股份有限公司时任监事； 杨红飞，广誉远中药股份有限公司时任董事、总经理、副总 经理； 李 众，广誉远中药股份有限公司时任副总经理； 赵选民，广誉远中药股份有限公司时任独立董事、董事会审 计委员会召集人。 一、上市公司及相关主体违规情况 根据中国证监会山西监管局《行政处罚决定书》（〔2024〕1 号、2 号、3 号、4 号、5 号、6 号、7 号、8 号）和《市场禁入 决定书》（〔2024〕1 号）（以下合称《决定书》）查明的事实，广 誉远中药股份有限公司（以下简称广誉远股份或公司）2016 年 至 2021 年年报"买断式销售"模式披露不真实，在子公司山西广 誉远 ...